Drug Profile
Iodine 131 actuximab - Shanghai Haikang Pharmaceutical
Alternative Names: 131I labeled actuximab - Shanghai Haikang Pharmaceutical; DK-001Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Shanghai Haikang Pharmaceutical
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Solid tumours
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for preclinical development in Colorectal-cancer in China (Injection)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Injection)